AR049922A1 - Procedimientos para aumentar la cantidad de hueso - Google Patents

Procedimientos para aumentar la cantidad de hueso

Info

Publication number
AR049922A1
AR049922A1 ARP050102506A ARP050102506A AR049922A1 AR 049922 A1 AR049922 A1 AR 049922A1 AR P050102506 A ARP050102506 A AR P050102506A AR P050102506 A ARP050102506 A AR P050102506A AR 049922 A1 AR049922 A1 AR 049922A1
Authority
AR
Argentina
Prior art keywords
pyk2
bone
procedures
optionally
refers
Prior art date
Application number
ARP050102506A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR049922A1 publication Critical patent/AR049922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a un procedimiento para estimular la funcion osteoblástica con un inhibidor de PYK2 en sujetos con osteoporosis, fracturas oseas, falta de uniones, seudoartrosis, enfermedad periodontal u otros trastornos del metabolismo de los huesos. Opcionalmente, el procedimiento comprende además la administracion de un segundo agente terapéutico oseo. También se refiere a procedimientos para identificar un inhibidor de PYK2 eficaz como agente terapéutico oseo, que comprende administrar un agente de prueba a una célula similar a osteoblasto y determinar si se estimula la funcion osteoblástica. Opcionalmente, el procedimiento de identificacion además comprende poner en contacto el agente de prueba con PYK2 y determinar si se inhibe la actividad de PYK2.
ARP050102506A 2004-06-21 2005-06-17 Procedimientos para aumentar la cantidad de hueso AR049922A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58140704P 2004-06-21 2004-06-21

Publications (1)

Publication Number Publication Date
AR049922A1 true AR049922A1 (es) 2006-09-13

Family

ID=35240963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102506A AR049922A1 (es) 2004-06-21 2005-06-17 Procedimientos para aumentar la cantidad de hueso

Country Status (9)

Country Link
US (1) US20090118316A1 (es)
EP (1) EP1765461A1 (es)
JP (1) JP2008503561A (es)
AR (1) AR049922A1 (es)
BR (1) BRPI0512342A (es)
CA (1) CA2571482A1 (es)
MX (1) MXPA06015170A (es)
TW (1) TW200613032A (es)
WO (1) WO2005123191A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402852B2 (en) * 2006-10-20 2016-08-02 Children's Medical Center Corporation Method to enhance tissue regeneration
ES2472323T3 (es) 2008-06-17 2014-06-30 Astrazeneca Ab Compuestos de piridina
AU2009308191A1 (en) 2008-10-24 2010-04-29 Warsaw Orthopedic, Inc. Compositions and methods for promoting bone formation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AU6163398A (en) * 1997-02-11 1998-08-26 Merck & Co., Inc. Identification of inhibitors of protein tyrosine kinase 2
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20030191162A1 (en) * 1998-12-31 2003-10-09 Sugen Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CA2571482A1 (en) 2005-12-29
TW200613032A (en) 2006-05-01
MXPA06015170A (es) 2007-08-21
US20090118316A1 (en) 2009-05-07
JP2008503561A (ja) 2008-02-07
WO2005123191A1 (en) 2005-12-29
EP1765461A1 (en) 2007-03-28
BRPI0512342A (pt) 2008-03-04

Similar Documents

Publication Publication Date Title
Fielding et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
Lambert et al. Electro-membrane microcurrent therapy reduces signs and symptoms of muscle damage
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
ATE297723T1 (de) Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
AR063149A1 (es) Formulaciones a base de polipeptidos estables
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
BR112013013460A8 (pt) métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
AR058182A1 (es) Metodos, composiciones y equipos par el tratamiento de afecciones medicas
WO2009137217A3 (en) Therapeutic replenishment and enrichment of ocular surface lubrication
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
CZ2006579A3 (cs) Kožní mikroaktivační systém
BR0316969A (pt) Tratamento de mal de huntington com epa
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
Johnston et al. A randomized controlled trial of a leg orthosis versus traditional treatment for soldiers with shin splints: a pilot study
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2006097933A3 (en) Method for monitoring changes in blood glucose level
AR049922A1 (es) Procedimientos para aumentar la cantidad de hueso

Legal Events

Date Code Title Description
FB Suspension of granting procedure